<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://thorax.bmj.com">
<title>Thorax current issue</title>
<link>http://thorax.bmj.com</link>
<description>Thorax RSS feed -- current issue</description>
<prism:coverDisplayDate>Feb  1 2012 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Thorax</prism:publicationName>
<prism:issn>0040-6376</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/i?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/97?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/98?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/100?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/102?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/106?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/111?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/116?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/117?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/122?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/132?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/138?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/139?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/147?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/156?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/157?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/163?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/164?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/170?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/171?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/177-a?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/177-b?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/177-c?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/178-a?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/178-b?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/178-c?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/178-d?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/178-e?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/179?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/183?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/185?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/67/2/187?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://thorax.bmj.com/site/homepage/Thorax_95x60.gif" />
</channel>
<image rdf:about="http://thorax.bmj.com/site/homepage/Thorax_95x60.gif">
<title>Thorax</title>
<url>http://thorax.bmj.com/site/homepage/Thorax_95x60.gif</url>
<link>http://thorax.bmj.com</link>
</image>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/i?rss=1">
<title><![CDATA[Highlights from this issue]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/i?rss=1</link>
<description><![CDATA[ <sec><st>Department of error!</st> <p><qd><p>&lsquo;Oh &ndash; let no-one ever, ever doubt,</p> <p>What nobody is sure about!&rsquo; (Hilaire Belloc)</p> </qd></p> <p>Hot off the Breath: the PANTHER-IPF trial dared to go where no man has gone before (at least for a very long time) and have a PLACEBO limb in a randomised controlled trial of treatment for IPF, and lo! Those randomised to the gold standard triple therapy arm did substantially worse, and this limb has rightly been terminated by the data monitoring board. On <b><I>page <addart type="iti" doi="10.1136/thoraxjnl-2011-201398">97</addart></I></b>, McGrath and Millar dissect the implications of this for the current treatment of IPF. As researchers and clinicians, we should also consider the wider implications: why was a high class placebo controlled randomised double blind trial of immunosuppressive therapy in IPF proposed by Jon Britton's group in Nottingham not supported in the early 1990s? How many patients have suffered harm because we have...]]></description>
<dc:creator><![CDATA[Bush, A., Pavord, I.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201572</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201572</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Highlights from this issue]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Airwaves</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>i</prism:startingPage>
<prism:endingPage>i</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/97?rss=1">
<title><![CDATA[Hot off the breath: triple therapy for idiopathic pulmonary fibrosis--hear the PANTHER roar]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/97?rss=1</link>
<description><![CDATA[ <p>Idiopathic pulmonary fibrosis (IPF) is a disease characterised by alveolar epithelial damage followed by an aberrant repair mechanism characterised by fibroblast foci and activated myofibroblasts.<cross-ref type="bib" refid="b1">1</cross-ref> Despite an incidence of 7.4/100 000 person years which is increasing year on year and a median survival of only 2&ndash;3&nbsp;years, there is paucity of evidence for effective therapy.<cross-ref type="bib" refid="b2">2</cross-ref> The current British Thoracic Society guidelines weakly recommend <I>N</I>-acetylcysteine (NAC), prednisolone and azathioprine (based on the IFIGENIA&mdash;Idiopathic Pulmonary Fibrosis International Group Exploring <I>N</I>-Acetylcysteine I Annual&mdash;trial) whereas the more recent guidelines of the American Thoracic Society/European Respiratory Society recommend lung transplantation or participation in a clinical trial as treatment options.<cross-ref type="bib" refid="b3">3&ndash;5</cross-ref><cross-ref type="bib" refid="b4"></cross-ref><cross-ref type="bib" refid="b5"></cross-ref></p> <p>&nbsp;Increasing recognition of the clinical need for effective IPF therapy has finally led to a number of clinical trials evaluating potential anti-inflammatory and anti-fibrotic agents. IFIGENIA demonstrated that triple therapy with NAC, azathioprine and prednisolone was better...]]></description>
<dc:creator><![CDATA[McGrath, E. E., Millar, A. B.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201398</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201398</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Hot off the breath: triple therapy for idiopathic pulmonary fibrosis--hear the PANTHER roar]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Editorial</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>97</prism:startingPage>
<prism:endingPage>98</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/98?rss=1">
<title><![CDATA[The asbestos disease epidemic: here today, here tomorrow]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/98?rss=1</link>
<description><![CDATA[ <p>In what may be the best ever use of a Wellcome grant, Geoffrey Tweedale, in his fascinating history of the multinational asbestos company Turner &amp; Newall,<cross-ref type="bib" refid="b1">1</cross-ref> reminds us that asbestos was once known as the &lsquo;magic mineral&rsquo;. Indeed, in many ways, it is the ideal construction material: tough, durable, light in weight, fire-resistant and very cheap. Unfortunately, asbestos is also, as every respiratory physician knows, highly toxic when inhaled. Total bans on its use are in place in 52 countries including those of the European Union, Australia, Japan and South Africa<cross-ref type="bib" refid="b2">2</cross-ref>; and its use is tightly restricted in the USA, New Zealand and Canada&mdash;the last, ironically, among the world's largest exporters of the material.</p> <p>&nbsp;Readers from these countries may be surprised to learn that elsewhere the production, sale and use of asbestos continue to flourish and even increase. In 1994, one of us (NP) edited...]]></description>
<dc:creator><![CDATA[Cullinan, P., Pearce, N.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201180</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201180</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[The asbestos disease epidemic: here today, here tomorrow]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Editorial</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>98</prism:startingPage>
<prism:endingPage>99</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/100?rss=1">
<title><![CDATA[Continuous versus intermittent inhaled corticosteroid (budesonide) for mild persistent asthma in children--not too much, not too little]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/100?rss=1</link>
<description><![CDATA[ <p>The clinical efficacy of inhaled corticosteroids (ICSs) in asthma has been demonstrated in long-term intervention studies,<cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> and ICSs are recommended first-line treatment of persistent asthma, even in children.<cross-ref type="bib" refid="b3">3</cross-ref> The long-term benefits of early intervention with ICS have been well documented in adults with asthma.<cross-ref type="bib" refid="b4">4</cross-ref> In children, early intervention with ICS has not altered the natural history of the disease.<cross-ref type="bib" refid="b1">1</cross-ref> We have recently finalised a series of studies related to the Helsinki Early Intervention Childhood Asthma Programme.<cross-ref type="bib" refid="b5">5</cross-ref> The programme highlights the benefits and safety aspects of intermittent treatment with an ICS, budesonide, in comparison with continuous daily ICS and non-steroidal maintenance treatment. In this study, we summarise our experiences.</p> <p>&nbsp;In the 18-month intervention, we compared two budesonide regimens with a control group treated with a fixed dose of disodium cromoglycate (DSCG). The study evaluated the antiasthmatic efficacy...]]></description>
<dc:creator><![CDATA[Turpeinen, M., Pelkonen, A. S., Selroos, O., Nikander, K., Haahtela, T.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200246</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200246</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Continuous versus intermittent inhaled corticosteroid (budesonide) for mild persistent asthma in children--not too much, not too little]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Editorial</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>100</prism:startingPage>
<prism:endingPage>102</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/102?rss=1">
<title><![CDATA[Continuous versus intermittent inhaled corticosteroids for mild persistent asthma in children: not too much, not too little]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/102?rss=1</link>
<description><![CDATA[ <p>The goal of asthma treatment is to prevent exacerbations, achieve daily asthma control and prevent adverse effects with a minimum of medication. In preschoolers, children and adolescents with mild persistent asthma, the most effective therapy remains daily use of low-dose inhaled corticosteroids.<cross-ref type="bib" refid="b1">1</cross-ref> Why then consider intermittent therapy over maintenance inhaled corticosteroids?</p> <p>&nbsp;The intermittent approach is attractive to patients and families for a variety of reasons, including fear of corticosteroid side effects,<cross-ref type="bib" refid="b2">2</cross-ref> the erroneous concept that no symptoms equate to no disease<cross-ref type="bib" refid="b3">3</cross-ref> and ease of compliance with medications administered for symptoms rather than on a daily basis. Indeed, pharmacy records clearly show that most children with asthma infrequently renew their prescriptions for controller medications, suggesting that they may not understand, perceive or agree with the need for daily therapy, despite ongoing healthcare resources utilisation and excess use of rescue &beta;2-agonist.<cross-ref type="bib" refid="b4">4</cross-ref></p> <p>This practice...]]></description>
<dc:creator><![CDATA[Ducharme, F. M.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200961</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200961</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Continuous versus intermittent inhaled corticosteroids for mild persistent asthma in children: not too much, not too little]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Editorial</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>102</prism:startingPage>
<prism:endingPage>105</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/106?rss=1">
<title><![CDATA[A 37-year observation of mortality in Chinese chrysotile asbestos workers]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/106?rss=1</link>
<description><![CDATA[
<sec><st>Objectives</st>
<p>This 37-year prospective cohort study was undertaken to provide additional evidence for mortality risks associated with exposure to chrysotile asbestos.</p>
</sec>
<sec><st>Methods</st>
<p>577 asbestos workers and 435 control workers in original cohorts were followed from 1972 to 2008, achieving a follow-up rate of 99% and 73%, respectively. Morality rates were determined based on person-years of observation. Cox proportional hazard models were constructed to estimate HRs of cause-specific mortality, while taking into account age, smoking and asbestos exposure level.</p>
</sec>
<sec><st>Results</st>
<p>There were 259 (45%) deaths identified in the asbestos cohort, and 96 died of all cancers. Lung cancer (n=53) and non-malignant respiratory diseases (n=81) were major cause-specific deaths, in contrast to nine lung cancers and 11 respiratory diseases in the controls. Age and smoking-adjusted HRs for mortality by all causes and all cancers in asbestos workers were 2.05 (95% CI 1.56 to 2.68) and 1.89 (1.25 to 2.87), respectively. The risks for lung cancer and respiratory disease deaths in asbestos workers were over threefold that in the controls (HR 3.31(95% CI 1.60 to 6.87); HR 3.23 (95% CI 1.68 to 6.22), respectively). There was a clear exposure&ndash;response trend with asbestos exposure level and lung cancer mortality in both smokers and non-smokers.</p>
</sec>
<sec><st>Conclusion</st>
<p>Data from this prospective cohort provide strong evidence for increased mortality risks, particularly from lung cancer and non-malignant respiratory diseases, associated with exposure to chrysotile asbestos, while taking into account of the smoking effect.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Wang, X., Yano, E., Qiu, H., Yu, I., Courtice, M. N., Tse, L. A., Lin, S., Wang, M.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200169</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200169</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lung neoplasms, Epidemiologic studies, Lung cancer (oncology), Lung cancer (respiratory medicine), Occupational and environmental medicine, Environmental issues, Health education, Smoking, Health effects of tobacco use, Tobacco use]]></dc:subject>
<dc:title><![CDATA[A 37-year observation of mortality in Chinese chrysotile asbestos workers]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Occupational lung disease</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>106</prism:startingPage>
<prism:endingPage>110</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/111?rss=1">
<title><![CDATA[Occupational exposure to organic dust increases lung cancer risk in the general population]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/111?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Organic dust is a complex mixture of particulate matter from microbial, plant or animal origin. Occupations with exposure to animal products have been associated with an increased lung cancer risk, while exposure to microbial components (eg, endotoxin) has been associated with a decreased risk. To date there has not been a comprehensive evaluation of the possible association between occupational organic dust exposure (and its specific constituents) and lung cancer risk in the general population.</p>
</sec>
<sec><st>Methods</st>
<p>The SYNERGY project has pooled information on lifetime working and smoking from 13 300 lung cancer cases and 16 273 controls from 11 case&ndash;control studies conducted in Europe and Canada. A newly developed general population job-exposure matrix (assigning no, low or high exposure to organic dust, endotoxin, and contact with animals or fresh animal products) was applied to determine level of exposure. ORs for lung cancer were estimated by logistic regression, adjusted for age, sex, study, cigarette pack-years, time since quitting smoking, and ever employment in occupations with established lung cancer risk.</p>
</sec>
<sec><st>Results</st>
<p>Occupational organic dust exposure was associated with increased lung cancer risk. The second to the fourth quartile of cumulative exposure showed significant risk estimates ranging from 1.12 to 1.24 in a dose-dependent manner (p&lt;0.001). This association remained in the highest quartile after restricting analyses to subjects without chronic obstructive pulmonary disease or asthma. No association was observed between lung cancer and exposure to endotoxin or contact with animals or animal products.</p>
</sec>
<sec><st>Conclusion</st>
<p>Occupational exposure to organic dust was associated with increased lung cancer risk in this large pooled case&ndash;control study.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Peters, S., Kromhout, H., Olsson, A. C., Wichmann, H.-E., Bruske, I., Consonni, D., Landi, M. T., Caporaso, N., Siemiatycki, J., Richiardi, L., Mirabelli, D., Simonato, L., Gustavsson, P., Plato, N., Jockel, K.-H., Ahrens, W., Pohlabeln, H., Boffetta, P., Brennan, P., Zaridze, D., Cassidy, A., Lissowska, J., Szeszenia-Dabrowska, N., Rudnai, P., Fabianova, E., Forastiere, F., Bencko, V., Foretova, L., Janout, V., Stucker, I., Dumitru, R. S., Benhamou, S., Bueno-de-Mesquita, B., Kendzia, B., Pesch, B., Straif, K., Bruning, T., Vermeulen, R.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200716</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200716</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lung neoplasms, Epidemiologic studies, Lung cancer (oncology), Asthma, Lung cancer (respiratory medicine), Environmental issues, Health education, Smoking, Health effects of tobacco use, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Occupational exposure to organic dust increases lung cancer risk in the general population]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Occupational lung disease</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>111</prism:startingPage>
<prism:endingPage>116</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/116?rss=1">
<title><![CDATA[Call for reviewers for journal club in Thorax]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/116?rss=1</link>
<description><![CDATA[ <p>A number of important papers are published in general medical or scientific journals or in specialist ones such as oncological, paediatric or epidemiological journals. Physicians and scientists may have varying access to these publications and thus may miss important new development in basic science or clinical medicine.</p> <p>Journal Club articles are summaries of papers that have been selected from these journals, printing the title of the paper with a short commentary of about 200&ndash;250 words, summarising the main message or learning point from the paper. These articles will be attributed to the reviewer and may include a personal view on the paper, especially if the topic is controversial. The articles, usually reporting original research rather than reviews or meta-analyses, are selected by the Journal Club editor from papers published within the last month and are then sent by email to the reviewers. We are keen to expand the bank...]]></description>
<dc:creator><![CDATA[Quint, J.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201619</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201619</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Call for reviewers for journal club in Thorax]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>116</prism:startingPage>
<prism:endingPage>116</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/117?rss=1">
<title><![CDATA[Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/117?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Rates of mortality and readmission are high in patients hospitalised with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). In this population, the prognostic value of the Medical Research Council Dyspnoea Scale (MRCD) is uncertain, and an extended MRCD (eMRCD) scale has been proposed to improve its utility. Coexistent pneumonia is common and, although the CURB-65 prediction tool is used, its discriminatory value has not been reported.</p>
</sec>
<sec><st>Methods</st>
<p>Clinical and demographic data were collected on consecutive patients hospitalised with AECOPD. The relationship of stable-state dyspnoea severity to in-hospital mortality and 28-day readmission was assessed. The discriminatory value of CURB-65, MRCD and eMRCD, in the prediction of in-hospital mortality, was assessed and compared.</p>
</sec>
<sec><st>Results</st>
<p>920 patients were recruited. 10.4% died in-hospital and 19.1% of the 824 survivors were readmitted within 28&nbsp;days of discharge. During their stable state prior to admission, 34.2% of patients were too breathless to leave the house. Mortality was significantly higher in pneumonic than in non-pneumonic exacerbations (20.1% vs 5.8%, p&lt;0.001). eMRCD was a significantly better discriminator than either CURB-65 or the traditional MRCD scale for predicting in-hospital mortality, and was a stronger prognostic tool than CURB-65 in the subgroup of patients with pneumonic AECOPD.</p>
</sec>
<sec><st>Conclusions</st>
<p>The severity of dyspnoea in the stable state predicts important clinical outcomes in patients hospitalised with AECOPD. The eMRCD scale identifies a subgroup of patients at a particularly high risk of in-hospital mortality and is a better predictor of mortality risk than CURB-65 in exacerbations complicated by pneumonia.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Steer, J., Norman, E. M., Afolabi, O. A., Gibson, G. J., Bourke, S. C.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200332</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200332</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Pneumonia (infectious disease), TB and other respiratory infections, Pneumonia (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Chronic obstructive pulmonary disease</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>117</prism:startingPage>
<prism:endingPage>121</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/122?rss=1">
<title><![CDATA[Gene expression networks in COPD: microRNA and mRNA regulation]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/122?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>The mechanisms underlying chronic obstructive pulmonary disease (COPD) remain unclear. MicroRNAs (miRNAs or <I>miRs</I>) are small non-coding RNA molecules that modulate the levels of specific genes and proteins. Identifying expression patterns of miRNAs in COPD may enhance our understanding of the mechanisms of disease. A study was undertaken to determine if miRNAs are differentially expressed in the lungs of smokers with and without COPD. miRNA and mRNA expression were compared to enrich for biological networks relevant to the pathogenesis of COPD.</p>
</sec>
<sec><st>Methods</st>
<p>Lung tissue from smokers with no evidence of obstructive lung disease (n=9) and smokers with COPD (n=26) was examined for miRNA and mRNA expression followed by validation. We then examined both miRNA and mRNA expression to enrich for relevant biological pathways.</p>
</sec>
<sec><st>Results</st>
<p>70 miRNAs and 2667 mRNAs were differentially expressed between lung tissue from subjects with COPD and smokers without COPD. miRNA and mRNA expression profiles enriched for biological pathways that may be relevant to the pathogenesis of COPD including the transforming growth factor &beta;, Wnt and focal adhesion pathways. miR-223 and <I>miR-1274a</I> were the most affected miRNAs in subjects with COPD compared with smokers without obstruction. <I>miR-15b</I> was increased in COPD samples compared with smokers without obstruction and localised to both areas of emphysema and fibrosis. <I>miR-15b</I> was differentially expressed within GOLD classes of COPD. Expression of SMAD7, which was validated as a target for <I>miR-15b</I>, was decreased in bronchial epithelial cells in COPD.</p>
</sec>
<sec><st>Conclusions</st>
<p>miRNA and mRNA are differentially expressed in individuals with COPD compared with smokers without obstruction. Investigating these relationships may further our understanding of the mechanisms of disease.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Ezzie, M. E., Crawford, M., Cho, J.-H., Orellana, R., Zhang, S., Gelinas, R., Batte, K., Yu, L., Nuovo, G., Galas, D., Diaz, P., Wang, K., Nana-Sinkam, S. P.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200089</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200089</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Gene expression networks in COPD: microRNA and mRNA regulation]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Chronic obstructive pulmonary disease</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>122</prism:startingPage>
<prism:endingPage>131</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/132?rss=1">
<title><![CDATA[Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/132?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>To determine differences in aetiologies, initial antimicrobial treatment choices and outcomes in patients with nursing-home-acquired pneumonia (NHAP) compared with patients with community-acquired pneumonia (CAP), which is a controversial issue.</p>
</sec>
<sec><st>Methods</st>
<p>Data from the prospective multicentre Competence Network for Community-acquired pneumonia (CAPNETZ) database were analysed for hospitalised patients aged &ge;65&nbsp;years with CAP or NHAP. Potential differences in baseline characteristics, comorbidities, physical examination findings, severity at presentation, initial laboratory investigations, blood gases, microbial investigations, aetiologies, antimicrobial treatment and outcomes were determined between the two groups.</p>
</sec>
<sec><st>Results</st>
<p>Patients with NHAP presented with more severe pneumonia as assessed by CRB-65 (confusion, respiratory rate, blood pressure, 65 years and older) score than patients with CAP but received the same frequency of mechanical ventilation and less antimicrobial combination treatment. There were no clinically relevant differences in aetiology, with <I>Streptococcus pneumoniae</I> the most important pathogen in both groups, and potential multidrug-resistant pathogens were very rare (&lt;5%). Only <I>Staphylococcus aureus</I> was more frequent in the NHAP group (n=12, 2.3% of the total population, 3.1% of those with microbial sampling compared with 0.7% and 0.8% in the CAP group, respectively). Short-term and long-term mortality in the NHAP group was higher than in the CAP group for patients aged &ge;65&nbsp;years (26.6% vs 7.2% and 43.8% vs 14.6%, respectively). However, there was no association between excess mortality and potential multidrug-resistant pathogens.</p>
</sec>
<sec><st>Conclusions</st>
<p>Excess mortality in patients with NHAP cannot be attributed to a different microbial pattern but appears to result from increased comorbidities, and consequently, pneumonia is frequently considered and managed as a terminal event.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Ewig, S., Klapdor, B., Pletz, M. W., Rohde, G., Schutte, H., Schaberg, T., Bauer, T. T., Welte, T., for the CAPNETZ study group]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200630</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200630</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Editor's choice, Pneumonia (infectious disease), TB and other respiratory infections, Mechanical ventilation, Airway biology, Mechanical ventilation, Pneumonia (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Respiratory infection</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>132</prism:startingPage>
<prism:endingPage>138</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/138?rss=1">
<title><![CDATA[Improved survival in cystic fibrosis patients with severely impaired lung function]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/138?rss=1</link>
<description><![CDATA[ <p>A forced expiratory volume in one second (FEV<SUB>1</SUB>) less than 30% predicted has been accepted as the threshold at which 50% of patients with cystic fibrosis (CF) survive 2&nbsp;years or less. However, this estimate, made in the early 1990s, does not take into account recent developments in treatment. This cohort study aimed to re-evaluate the survival of CF patients with severely impaired lung function.</p> <p>Two hundred and seventy-six CF patients whose FEV<SUB>1</SUB> was first observed to be less than 30% predicted between 1990 and 2003 were included in the cohort. The patients were followed up in 2-year subcohorts until 2007 and their survival was assessed. The authors showed an important improvement in the average survival of CF patients with severely impaired lung function. Median survival for patients who entered the cohort most recently (2002&ndash;2003) was 5.3&nbsp;years, more than four times that for those who entered the study in the...]]></description>
<dc:creator><![CDATA[Narwani, V.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200357</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200357</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Improved survival in cystic fibrosis patients with severely impaired lung function]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>138</prism:startingPage>
<prism:endingPage>138</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/139?rss=1">
<title><![CDATA[Proteasomal inhibition after injury prevents fibrosis by modulating TGF-{beta}1 signalling]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/139?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>The development of organ fibrosis after injury requires activation of transforming growth factor &beta;<SUB>1</SUB> which regulates the transcription of profibrotic genes. The systemic administration of a proteasomal inhibitor has been reported to prevent the development of fibrosis in the liver, kidney and bone marrow. It is hypothesised that proteasomal inhibition would prevent lung and skin fibrosis after injury by inhibiting TGF-&beta;<SUB>1</SUB>-mediated transcription.</p>
</sec>
<sec><st>Methods</st>
<p>Bortezomib, a small molecule proteasome inhibitor in widespread clinical use, was administered to mice beginning 7&nbsp;days after the intratracheal or intradermal administration of bleomycin and lung and skin fibrosis was measured after 21 or 40&nbsp;days, respectively. To examine the mechanism of this protection, bortezomib was administered to primary normal lung fibroblasts and primary lung and skin fibroblasts obtained from patients with idiopathic pulmonary fibrosis and scleroderma, respectively.</p>
</sec>
<sec><st>Results</st>
<p>Bortezomib promoted normal repair and prevented lung and skin fibrosis when administered beginning 7&nbsp;days after the initiation of bleomycin. In primary human lung fibroblasts from normal individuals and patients with idiopathic pulmonary fibrosis and in skin fibroblasts from a patient with scleroderma, bortezomib inhibited TGF-&beta;<SUB>1</SUB>-mediated target gene expression by inhibiting transcription induced by activated Smads. An increase in the abundance and activity of the nuclear hormone receptor PPAR, a repressor of Smad-mediated transcription, contributed to this response.</p>
</sec>
<sec><st>Conclusions</st>
<p>Proteasomal inhibition prevents lung and skin fibrosis after injury in part by increasing the abundance and activity of PPAR. Proteasomal inhibition may offer a novel therapeutic alternative in patients with dysregulated tissue repair and fibrosis.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Mutlu, G. M., Budinger, G. R. S., Wu, M., Lam, A. P., Zirk, A., Rivera, S., Urich, D., Chiarella, S. E., Go, L. H. T., Ghosh, A. K., Selman, M., Pardo, A., Varga, J., Kamp, D. W., Chandel, N. S., Sznajder, J. I., Jain, M.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200717</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200717</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Chemotherapy, Interstitial lung disease]]></dc:subject>
<dc:title><![CDATA[Proteasomal inhibition after injury prevents fibrosis by modulating TGF-{beta}1 signalling]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Interstitial lung disease</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>139</prism:startingPage>
<prism:endingPage>146</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/147?rss=1">
<title><![CDATA[Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/147?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Idiopathic pulmonary fibrosis (IPF) is characterised by the aberrant epithelial to mesenchymal transition (EMT) and myofibroblast accumulation. Sphingosine-1-phosphate (S1P) and sphingosine kinase 1 (SPHK1) have been implicated in lung myofibroblast transition, but their role in EMT and their expression in patients with IPF is unknown.</p>
</sec>
<sec><st>Methods and results</st>
<p>S1P levels were measured in serum (n=27) and bronchoalveolar lavage (BAL; n=15) from patients with IPF and controls (n=30 for serum and n=15 for BAL studies). SPHK1 expression was measured in lung tissue from patients with IPF (n=12) and controls (n=15). Alveolar type II transformation into mesenchymal cells was studied in response to S1P (10<sup>&ndash;9</sup>&ndash;10<sup>&ndash;5</sup> M). The median (IQR) of S1P serum levels was increased in patients with IPF (1.4 (0.4)&nbsp;&mu;M) versus controls (1 (0.26)&nbsp;&mu;M; p&lt;0.0001). BAL S1P levels were increased in patients with IPF (1.12 (0.53)&nbsp;&mu;M) versus controls (0.2 (0.5); p&lt;0.0001) and correlated with diffusion capacity of the lung for carbon monoxide, forced expiratory volume in 1 s and forced vital capacity (Spearman's r=&ndash;0.87, &ndash;0.72 and &ndash;0.68, respectively) in patients with IPF. SPHK1 was upregulated in lung tissue from patients with IPF and correlated with &alpha;-smooth muscle actin, vimentin and collagen type I (Spearman's r=0.82, 0.85 and 0.72, respectively). S1P induced EMT in alveolar type II cells by interacting with S1P<SUB>2</SUB> and S1P<SUB>3</SUB>, as well as by the activation of p-Smad3, RhoA-GTP, oxidative stress and transforming growth factor-&beta;1 (TGF-&beta;1) release. Furthermore, TGF-&beta;1-induced EMT was partially conducted by the S1P/SPHK1 activation, suggesting crosstalk between TGF-&beta;1 and the S1P/SPHK1 axis.</p>
</sec>
<sec><st>Conclusions</st>
<p>S1P is elevated in patients with IPF, correlates with the lung function and mediates EMT.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Milara, J., Navarro, R., Juan, G., Peiro, T., Serrano, A., Ramon, M., Morcillo, E., Cortijo, J.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200026</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200026</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Airway biology, Interstitial lung disease, Lung function]]></dc:subject>
<dc:title><![CDATA[Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Interstitial lung disease</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>147</prism:startingPage>
<prism:endingPage>156</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/156?rss=1">
<title><![CDATA[Environmental micro-organisms and childhood asthma: the more the merrier?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/156?rss=1</link>
<description><![CDATA[ <p>Epidemiological studies have shown that children who grow up on traditional farms are protected from atopic conditions, including asthma. However, how this protection arises is not clearly understood. It has been postulated that immunological responses to an increased microbial exposure in early childhood is important. This study investigates, specifically, whether it is the <I>variety</I> of microbial exposure that is protective.</p> <p>Two cross-sectional studies are described (PARSIFAL n=489 and GABRIELA n=444) in which the prevalence of asthma and atopy in children who live on farms are compared with a control group. Samples of dust were collected from children's bedrooms and analysed for bacteria and fungi. Results showed that the farm-dwelling children were exposed to a greater diversity of micro-organisms, even in an indoor environment. Furthermore, the prevalence of asthma was inversely related to the greater diversity of microbial exposure, independent of whether the children lived on a farm or not....]]></description>
<dc:creator><![CDATA[Srikanthan, K.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200404</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200404</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Environmental micro-organisms and childhood asthma: the more the merrier?]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>156</prism:startingPage>
<prism:endingPage>156</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/157?rss=1">
<title><![CDATA[Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/157?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Respiratory failure is a life-threatening and unpredictable complication of systemic sclerosis (SSc). A study was undertaken to assess the value of alveolar nitric oxide (NO) in predicting the risk of lung function deterioration leading to respiratory failure or death in patients with SSc.</p>
</sec>
<sec><st>Methods</st>
<p>105 patients with SSc were enrolled in this prospective cohort and were followed longitudinally over a 3-year period during which the risk of occurrence of deleterious events was analysed according to alveolar concentration (C<SUB>A</SUB><scp>no</scp>), conducting airway output (J'<SUB>aw</SUB><scp>no</scp>) and fractional concentration (F<SUB>E</SUB><scp>no</scp><SUB>0.05</SUB>) of exhaled NO measured at inclusion. Comparison was made between each NO parameter to predict the occurrence of deleterious events, defined as a 10% decrease in total lung capacity or forced vital capacity from baseline, or death.</p>
</sec>
<sec><st>Results</st>
<p>The area under the receiver operating characteristic curve of C<SUB>A</SUB><scp>no</scp> to predict the occurrence of the combined events was 0.84 (95% CI 0.76 to 0.92; p&lt;0.001), which was significantly higher than those of J'<SUB>aw</SUB><scp>no</scp> and F<SUB>E</SUB><scp>no</scp><SUB>0.05</SUB> (p&lt;0.001). A cut-off of C<SUB>A</SUB><scp>no</scp> of 5.3&nbsp;ppb had a sensitivity of 88% and a specificity of 62% for the prediction of the occurrence of combined events during follow-up, and was validated in an independent cohort of patients with SSc. Combined events occurred more frequently in patients whose C<SUB>A</SUB><scp>no</scp> was &gt;5.3&nbsp;ppb. The adjusted HR for patients with C<SUB>A</SUB><scp>no</scp> &gt;5.3&nbsp;ppb was 6.06 (95% CI 2.36 to 15.53; p&lt;0.001). C<SUB>A</SUB><scp>no</scp> accurately predicted the occurrence of combined events irrespective of forced vital capacity values or the presence of interstitial lung disease at baseline.</p>
</sec>
<sec><st>Conclusions</st>
<p>Increased C<SUB>A</SUB><scp>no</scp> accurately identifies patients with SSc with a high risk of developing lung function deterioration and may help to initiate early appropriate treatment.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Tiev, K. P., Hua-Huy, T., Kettaneh, A., Allanore, Y., Le-Dong, N.-N., Duong-Quy, S., Cabane, J., Dinh-Xuan, A. T.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200499</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200499</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Airway biology, Interstitial lung disease, Lung function]]></dc:subject>
<dc:title><![CDATA[Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Exhaled markers</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>157</prism:startingPage>
<prism:endingPage>163</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/163?rss=1">
<title><![CDATA[Lectin-mediated innate defences are important in limiting disease in influenza]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/163?rss=1</link>
<description><![CDATA[ <p>The innate immune system is an important defence against previously unencountered pathogens. It recognises surface glycans through cell-associated and soluble lectin-mediated defences. This study investigates the effect of blocking these defences on antiviral activities and disease severity in influenza infection.</p> <p>Mice were infected with two influenza viruses that differ in the degree of glycosylation of the surface glycoprotein haemagluttinin. Infection with the poorly glycosylated H1N1 virus PR8 resulted in rapid weight loss and a 100% 5-day mortality, whereas the highly glycosylated PR8 reassortant BJx109 resulted in no significant weight loss and a 0% 10-day mortality. This result was replicated in knockout mice with impaired B and T cell function demonstrating that the innate immune system was sufficient to limit disease.</p> <p>In vitro only the highly glycosylated BJx109 (H3N2) virus infected airway macrophages to high levels and was neutralised by mouse bronchoalveolar lavage and a soluble lectin present in respiratory...]]></description>
<dc:creator><![CDATA[Kumar, N.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200358</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200358</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Lectin-mediated innate defences are important in limiting disease in influenza]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>163</prism:startingPage>
<prism:endingPage>163</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/164?rss=1">
<title><![CDATA[Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/164?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Studies in cystic fibrosis (CF) generally focus on inflammation present in the airway lumen. Little is known about inflammation occurring in the airway wall, the site ultimately destroyed in end-stage disease.</p>
</sec>
<sec><st>Objective</st>
<p>To test the hypothesis that inflammatory patterns in the lumen do not reflect those in the airway wall of children with CF.</p>
</sec>
<sec><st>Methods</st>
<p>Bronchoalveolar lavage (BAL) fluid and endobronchial biopsies were obtained from 46 children with CF and 16 disease-free controls. BAL cell differential was assessed using May-Gruenwald-stained cytospins. Area profile counts of bronchial tissue immunopositive inflammatory cells were determined.</p>
</sec>
<sec><st>Results</st>
<p>BAL fluid from children with CF had a predominance of neutrophils compared with controls (median 810<FONT FACE="arial,helvetica">x</FONT>10<sup>3</sup>/ml vs 1<FONT FACE="arial,helvetica">x</FONT>10<sup>3</sup>/ml, p&lt;0.0001). In contrast, subepithelial bronchial tissue from children with CF was characterised by a predominance of lymphocytes (median 961 vs 717&nbsp;cells/mm<sup>2</sup>, p=0.014), of which 82% were (CD3) T lymphocytes. In chest exacerbations, BAL fluid from children with CF had more inflammatory cells of all types compared with those with stable disease whereas, in biopsies, only the numbers of lymphocytes and macrophages, but not of neutrophils, were higher. A positive culture of <I>Pseudomonas aeruginosa</I> was associated with higher numbers of T lymphocytes in subepithelial bronchial tissue (median 1174 vs 714&nbsp;cells/mm<sup>2</sup>, p=0.029), but no changes were seen in BAL fluid. Cell counts in BAL fluid and biopsies were positively correlated with age but were unrelated to each other.</p>
</sec>
<sec><st>Conclusion</st>
<p>The inflammatory response in the CF airway is compartmentalised. In contrast to the neutrophil-dominated inflammation present in the airway lumen, the bronchial mucosa is characterised by the recruitment and accumulation of lymphocytes.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Regamey, N., Tsartsali, L., Hilliard, T. N., Fuchs, O., Tan, H.-L., Zhu, J., Qiu, Y.-S., Alton, E. W. F. W., Jeffery, P. K., Bush, A., Davies, J. C.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200585</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200585</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Inflammation, Cystic fibrosis]]></dc:subject>
<dc:title><![CDATA[Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Cystic fibrosis</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>164</prism:startingPage>
<prism:endingPage>170</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/170?rss=1">
<title><![CDATA[Role of kinase suppressor of Ras-1 in Pseudomonas aeruginosa infections]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/170?rss=1</link>
<description><![CDATA[ <p>Respiratory infection with <I>Pseudomonas aeruginosa</I> can have serious implications, particularly on a background of immunodeficiency, cystic fibrosis and mechanical ventilation. In this study, by conducting a series of experiments on mice, the authors identified the key role of the kinase suppressor of Ras-1 (Ksr1), an enzymatic protein, in the innate host response to <I>P aeruginosa</I> infection.</p> <p>Ksr1 deficiency impairs the bactericidal activity of alveolar macrophages and, as a consequence, Ksr1-deficient mice were found to die of sepsis from failed clearance of <I>P aeruginosa</I>. The bactericidal activity of alveolar macrophages and neutrophils is mediated by the formation and release of nitric oxide (NO) and peroxynitrite, which is triggered by Ksr1. This occurs through a previously unidentified pathway where Ksr1 functions as a unique scaffold and mediates the interaction between inducible NO synthase (iNOS) and heat shock protein 90, thereby activating iNOS and releasing NO, which kills the bacteria.</p> <p>The authors...]]></description>
<dc:creator><![CDATA[Huq, S.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200360</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200360</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Role of kinase suppressor of Ras-1 in Pseudomonas aeruginosa infections]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>170</prism:startingPage>
<prism:endingPage>170</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/171?rss=1">
<title><![CDATA[Thorax in focus: chronic obstructive pulmonary disease]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/171?rss=1</link>
<description><![CDATA[
<p>Keeping up to date with scientific developments in any field of medicine is challenging, and chronic obstructive pulmonary disease (COPD) is no exception. <I>Thorax</I> has played an important part in the communication of key developments to its readership. In this article we review original research published in the journal over the last 2-3 years. We consider scientific and clinical developments in the epidemiology, mechanisms and treatment of COPD, placing these articles in the context of other relevant literature in COPD.</p>
]]></description>
<dc:creator><![CDATA[Hodgson, D. B., Saini, G., Bolton, C. E., Steiner, M. C.]]></dc:creator>
<dc:date>2012-01-25T02:56:32-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201231</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201231</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Thorax in focus: chronic obstructive pulmonary disease]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Review</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>171</prism:startingPage>
<prism:endingPage>176</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/177-a?rss=1">
<title><![CDATA[Should bronchoscopy be advocated to study airway remodelling and inflammation in adults with cystic fibrosis?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/177-a?rss=1</link>
<description><![CDATA[ <p>We read with interest the article by Regamey <I>et al</I> who reviewed the relationship of airway remodelling to inflammation in cystic fibrosis (CF).<cross-ref type="bib" refid="b1">1</cross-ref> The authors suggested that endobronchial biopsy studies are useful for studying airway remodelling in CF. Four studies were conducted in 91 children who underwent bronchoscopy for clinical reasons or annual routine surveillance. These studies confirmed that airway remodelling in CF appeared early in life and this is indeed of more than academic interest. However, while the authors have previously shown and claimed that biopsy procedures are safe in infants and small children, the ethics of the procedure in children have been discussed by others.<cross-ref type="bib" refid="b2">2</cross-ref></p> <p>We would like to raise concerns about the procedure in adults as well. From 1987 to 2011, Regamey <I>et al</I> found five independent studies in which bronchial biopsies were performed in only 25 adults with CF.<cross-ref type="bib" refid="b1">1</cross-ref>...]]></description>
<dc:creator><![CDATA[Burgel, P.-R., Martin, C., Fajac, I., Dusser, D. J.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200824</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200824</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Should bronchoscopy be advocated to study airway remodelling and inflammation in adults with cystic fibrosis?]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>177</prism:startingPage>
<prism:endingPage>177</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/177-b?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/177-b?rss=1</link>
<description><![CDATA[
<p>We thank Burgel and colleagues for their valuable comments.<cross-ref type="bib" refid="b1">1</cross-ref> We agree that a cautious approach should be adopted when considering the use of bronchoscopy and biopsy in cystic fibrosis (CF) research. As stated in our review article,<cross-ref type="bib" refid="b2">2</cross-ref> we have confirmed the safety of endobronchial biopsy in children and infants with CF. Reassuringly, we have encountered no complications even in children with advanced lung disease. We advocate the use of endobronchial biopsy to investigate mechanisms of airway remodelling events and their relationship to infection and inflammation in children, but claim no experience of bronchoscopy in adult CF. It would be inappropriate for us to comment on the role of bronchoscopy in adults.</p>
<p><fn><no>Competing interests</no><p>None.</p>
</fn></p>
<p><fn><no>Contributors</no><p>All authors contributed to this letter equally.</p>
</fn></p>
<p><fn><no>Provenance and peer review</no><p>Not commissioned; internally peer reviewed.</p>
</fn></p>]]></description>
<dc:creator><![CDATA[Regamey, N., Jeffery, P. K., Alton, E. W. F. W., Bush, A., Davies, J. C.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200913</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200913</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>177</prism:startingPage>
<prism:endingPage>177</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/177-c?rss=1">
<title><![CDATA[The cloud of pulmonary embolism during COPD exacerbation]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/177-c?rss=1</link>
<description><![CDATA[ <p>We read with great interest the paper of Chang <I>et al</I>,<cross-ref type="bib" refid="b1">1</cross-ref> published recently in <I>Thorax.</I> We totally agree with the fact that &lsquo;cardiac involvement may be an important determinant of prognosis in COPD exacerbations&rsquo;. In their study, Chang <I>et al</I> found that patients presenting with COPD exacerbation (defined as dyspnoea, cough or sputum purulence, respiratory failure&mdash;Po<SUB>2</SUB>&lt;60&nbsp;mm&nbsp;Hg or Pco<SUB>2</SUB>&gt;45&nbsp;mm&nbsp;Hg&mdash;or change in mental status due to COPD) experience a worse prognosis if they also have high levels of troponin T and/or NT-proBNP.</p> <p>However, a potential important confounding factor may explain a part of their results: undiagnosed pulmonary embolism (PE), mimicking (or induced by) COPD exacerbation. Troponin and BNP are factors associated with poor prognosis in PE.<cross-ref type="bib" refid="b2">2</cross-ref> COPD is associated with an increased risk of deep venous thrombosis and PE (particularly during exacerbation) and with an increased risk of fatal PE.<cross-ref type="bib" refid="b3">3</cross-ref> In particular, COPD is associated...]]></description>
<dc:creator><![CDATA[Bertoletti, L., Mismetti, P., Decousus, H.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200416</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200416</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[The cloud of pulmonary embolism during COPD exacerbation]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>177</prism:startingPage>
<prism:endingPage>178</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/178-a?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/178-a?rss=1</link>
<description><![CDATA[ <p>We thank Bertoletti and colleagues for raising the important issue of pulmonary embolism (PE) in the exacerbation of chronic obstructive pulmonary disease (COPD).<cross-ref type="bib" refid="b1">1</cross-ref> Although we did not routinely investigate for PE in our cohort, we excluded any patients with suspected or confirmed PE from the study.<cross-ref type="bib" refid="b2">2</cross-ref> Unfortunately, it is difficult to detect thromboembolic events in this population and it is possible that we included some patients with subclinical pulmonary emboli. It is also plausible that this contributed to the association between elevated cardiac biomarkers and mortality. However, we think that this is unlikely to be the only mechanism.</p> <p>Thromboprophylaxis was administered to some patients during their admission depending on their immobility and other risk factors, but this would not have influenced the NT-proBNP or troponin T results obtained on presentation. We did not collect information on pre-existing anticoagulation therapy on admission to the study.</p> <p>Further...]]></description>
<dc:creator><![CDATA[Chang, C. L., Hancox, R. J.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200512</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200512</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>178</prism:startingPage>
<prism:endingPage>178</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/178-b?rss=1">
<title><![CDATA[Correction]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/178-b?rss=1</link>
<description><![CDATA[
<p><addart type="err" vol="66" pg="A128-b" doi="10.1136/thoraxjnl-2011-201054c.151"><I>Thorax</I> 2011;<b>66</b>:A128&ndash;A129</addart> doi:10.1136/thoraxjnl-2011-201054c.151. P151 Cost of pulmonary rehabilitation is offset by reduction in healthcare utilisation. The author list and author affiliations for this poster should read: <sup>1</sup> S Kibe, <sup>1</sup> D Ford, <sup>2</sup> S Hart. 1 Scarborough General Hospital, Scarborough, UK; 2 Castle Hill Hospital, Hull, UK.</p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201054c.151corr1</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201054c.151corr1</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Correction]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>178</prism:startingPage>
<prism:endingPage>178</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/178-c?rss=1">
<title><![CDATA[Correction]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/178-c?rss=1</link>
<description><![CDATA[
<p><addart type="err" vol="66" pg="A133-b" doi="10.1136/thoraxjnl-2011-201054c.163"><I>Thorax</I> 2011;<b>66</b>:A133&ndash;A134</addart> doi:10.1136/thoraxjnl-2011-201054c.163. P163 Factors influencing histological confirmation of diagnosis in lung cancer patients. The author list for this poster should read: S Chandramouli, M Cheema, J Corless. Wirral Lung Unit, Arrowe Park Hospital, Wirral CH49 5PE, UK.</p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201054c.163corr1</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201054c.163corr1</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Correction]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>178</prism:startingPage>
<prism:endingPage>178</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/178-d?rss=1">
<title><![CDATA[Correction]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/178-d?rss=1</link>
<description><![CDATA[
<p><addart type="err" vol="66" pg="A162-c" doi="10.1136/thoraxjnl-2011-201054c.233"><I>Thorax</I> 2011;<b>66</b>:A162&ndash;A163</addart> doi:10.1136/thoraxjnl-2011-201054c.233. P233 Judicious use of oximetry can help deliver cost effective sleep service. The author list and affiliation for this poster should read: C L Collins, B Balakrishnan, J Madieros, M Sovani. Queen's Medical Centre, Nottingham University Hospitals, Nottingham, UK.</p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201054c.233corr1</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201054c.233corr1</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Correction]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>178</prism:startingPage>
<prism:endingPage>178</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/178-e?rss=1">
<title><![CDATA[Correction]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/178-e?rss=1</link>
<description><![CDATA[
<p><addart type="err" vol="66" pg="A140-b" doi="10.1136/thoraxjnl-2011-201054c.179"><I>Thorax</I> 2011;<b>66</b>:A140</addart> doi:10.1136/thoraxjnl-2011-201054c.179. P179 The changing numbers and indications of mediastinoscopy procedures performed following the introduction of endobronchical ultrasound at a UK tertiary centre. The author list and affiliations for this poster should read: <sup>1</sup>M Bakir, <sup>2</sup>R Breen, <sup>2</sup>A Quinn, <sup>2</sup>J King, <sup>1</sup>G Santis. 1 Kings College London, London, UK; 2 Guy's and St Thomas' NHS Foundation Trust, London, UK.</p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201054c.179corr1</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201054c.179corr1</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Correction]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>178</prism:startingPage>
<prism:endingPage>178</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/179?rss=1">
<title><![CDATA[In search of the fibrotic epithelial cell: opportunities for a collaborative network]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/179?rss=1</link>
<description><![CDATA[
<p>Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown aetiology. It has a very poor prognosis and no effective treatment. There are two major barriers to the development of novel treatments in IPF: an incomplete understanding of its pathogenesis and the fact that current models of the disease are poorly predictive of therapeutic response. Recent studies suggest an important role for the alveolar epithelium in the pathogenesis of IPF. However, practical limitations associated with isolation and culture of primary alveolar epithelial cells have hampered progress towards further elucidating their role in the pathogenesis of the disease or developing disease models that accurately reflect the epithelial contribution. The practical limitations of primary alveolar epithelial cell culture can be divided into technical, logistical and regulatory hurdles that need to be overcome to ensure rapid progress towards improved treatment for patients with IPF. To develop a strategy to facilitate alveolar epithelial cell harvest, retrieval and sharing between IPF research groups and to determine how these cells contribute to IPF, a workshop was organised to discuss the central issues surrounding epithelial cells in IPF (ECIPF). The central themes discussed in the workshop have been compiled as the proceedings of the ECIPF.</p>
]]></description>
<dc:creator><![CDATA[Jenkins, G., Blanchard, A., Borok, Z., Bradding, P., Ehrhardt, C., Fisher, A., Hirani, N., Johnson, S., Konigshoff, M., Maher, T. M., Millar, A., Parfrey, H., Scotton, C., Tetley, T., Thickett, D., Wolters, P., on behalf of the contributors to the ECIPF workshop]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200195</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200195</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Interstitial lung disease]]></dc:subject>
<dc:title><![CDATA[In search of the fibrotic epithelial cell: opportunities for a collaborative network]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>179</prism:startingPage>
<prism:endingPage>182</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/183?rss=1">
<title><![CDATA[MicroRNAs in lung diseases]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/183?rss=1</link>
<description><![CDATA[
<p>The advent of RNA sequencing technology has stimulated rapid advances in our understanding of the transcriptome, including discovery of the vast RNA complement generated by transcript splice variation and the expansion of our knowledge of non-coding RNAs. One non-coding RNA subtype, microRNAs (miRNAs), are particularly well studied, primarily because of their important roles as post-transcriptional gene regulators. The first miRNA was identified in the early 1990s and there are now thought to be around 1000 distinct miRNAs in man, with each cell type expressing a distinct repertoire. Increasing evidence has implicated miRNAs as having causative roles in a variety of lung diseases and has driven investigations into their potential as therapeutic targets.</p>
]]></description>
<dc:creator><![CDATA[Pagdin, T., Lavender, P.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200532</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200532</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[MicroRNAs in lung diseases]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>183</prism:startingPage>
<prism:endingPage>184</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/185?rss=1">
<title><![CDATA[Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/185?rss=1</link>
<description><![CDATA[
<p>PulMiCC (Pulmonary Metastasectomy in Colorectal Cancer) is a randomised controlled trial funded by Cancer Research UK. Patients with a history of resected colorectal cancer who are found to have pulmonary metastases are first registered for evaluation and, if subsequently eligible for the trial, they are invited to be randomly allocated to &lsquo;active monitoring&rsquo; or &lsquo;active monitoring with pulmonary metastasectomy&rsquo;. The clinical outcomes are overall survival, relapse-free survival, lung function and patient-reported quality of life.</p>
]]></description>
<dc:creator><![CDATA[Treasure, T., Fallowfield, L., Lees, B., Farewell, V.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200015</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200015</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology)]]></dc:subject>
<dc:title><![CDATA[Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>185</prism:startingPage>
<prism:endingPage>187</prism:endingPage>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/67/2/187?rss=1">
<title><![CDATA[Pulmonary hamartoma mimicking primary bronchoalveolar cell carcinoma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/67/2/187?rss=1</link>
<description><![CDATA[ <p>A 52-year-old man with transitional cell carcinoma underwent a chest CT because of a newly developed pulmonary nodule observed on a chest radiograph. In addition to the nodule, a 2.8<FONT FACE="arial,helvetica">x</FONT>2.4&nbsp;cm well-circumscribed, pure ground-glass opacity with air cyst formation was incidentally found (<cross-ref type="fig" refid="fig1">figure 1</cross-ref>). There was no evidence of calcification or fat, and primary bronchoalveolar cell carcinoma was highly suspected. When performing preoperative CT-guided needle localisation of the opacity 2&nbsp;weeks later, we found that the lesion remained unchanged. After video-assisted thoracoscopic wedge resection, the initial nodule on the chest radiograph proved to be a metastatic lesion, but the ground-glass opacity was pathologically diagnosed as a hamartoma (<cross-ref type="fig" refid="fig2">figure 2</cross-ref>).</p> <sec><st>Discussion</st> <p>In a CT image, pulmonary hamartomas are typically well-defined nodules occasionally containing fat or regions of calcification or both.<cross-ref type="bib" refid="b1">1</cross-ref> Atypical presentations, such as a cystic mass or a soft-tissue nodule without fat or calcification, have...]]></description>
<dc:creator><![CDATA[Huang, C.-C., Sheu, C.-Y., Tzen, C.-Y., Huang, W.-C.]]></dc:creator>
<dc:date>2012-01-20T01:20:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200914</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200914</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Images in Thorax, Journalology, Pneumonia (infectious disease), TB and other respiratory infections, Pneumonia (respiratory medicine), Radiology (diagnostics), Ethics]]></dc:subject>
<dc:title><![CDATA[Pulmonary hamartoma mimicking primary bronchoalveolar cell carcinoma]]></dc:title>
<prism:publicationDate>2012-02-01</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
<prism:volume>67</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>187</prism:startingPage>
<prism:endingPage>188</prism:endingPage>
</item>
</rdf:RDF>
